By Kevin Penton ( July 6, 2015, 9:36 PM EDT) -- Endo Pharmaceuticals Inc. and Impax Laboratories sought Friday to dismiss proposed class actions claiming Endo paid more that $112 million to delay a generic version of painkiller Opana ER, saying the plaintiffs hadn't stated a claim under the U.S. Supreme Court's Actavis ruling....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.